keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant and gastric cancer

keyword
https://www.readbyqxmd.com/read/28535156/phase-ii-study-of-neoadjuvant-imatinib-in-large-gastrointestinal-stromal-tumours-of-the-stomach
#1
Yukinori Kurokawa, Han-Kwang Yang, Haruhiko Cho, Min-Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk-Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong-Ho Kong, Toshio Shimokawa, Jeong-Hwan Yook, Yuichiro Doki, Seock-Ah Im, Seiichi Hirota, Seokyung Hahn, Toshirou Nishida, Yoon-Koo Kang
BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate. RESULTS: A total of 56 patients were enroled in this study...
May 23, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28529985/recent-trends-of-gastric-cancer-treatment-in-turkey
#2
REVIEW
Ali Guner
Gastric cancer is the fifth most common type of cancer and is the fourth most common death due to cancer in Turkey. Incidence and mortality rates are one of the highest among European countries. Despite the high rates, management of gastric cancer is still an issue of debate in Turkey and national guidelines have yet to be established. While the treatment plan following the diagnosis of gastric cancer is determined by a multidisciplinary meeting at high-volume centers, the plan in the majority of cases in Turkey is decided based on the decision of an individual physician...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28526077/the-optimal-extent-of-gastrectomy-for-middle-third-gastric-cancer-distal-subtotal-gastrectomy-is-superior-to-total-gastrectomy-in-short-term-effect-without-sacrificing-long-term-survival
#3
Xin Ji, Yan Yan, Zhao-De Bu, Zi-Yu Li, Ai-Wen Wu, Lian-Hai Zhang, Xiao-Jiang Wu, Xiang-Long Zong, Shuang-Xi Li, Fei Shan, Zi-Yu Jia, Jia-Fu Ji
BACKGROUND: The optimal extent of gastrectomy for middle-third gastric cancer remains controversial. In our study, the short-term effects and longer-term survival outcomes of distal subtotal gastrectomy and total gastrectomy are analysed to determine the optimal extent of gastrectomy for middle-third gastric cancer. METHODS: We retrospectively collect and analyse clinicopathologic data and follow-up outcomes from a prospectively collected database at the Peking University Cancer Hospital...
May 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28512415/neoadjuvant-chemotherapy-and-adjuvant-chemoradiation-therapy-in-the-treatment-of-resected-gastric-adenocarcinoma-a-case-series
#4
Christina Hadzitheodorou, Rebecca A Moss, Timothy J Kennedy, Salma K Jabbour
The treatment of gastric cancer requires a multimodal approach to decrease the risk of locoregional and distant recurrence. The optimal timing of chemotherapy, surgery, and radiation therapy continues to be explored in ongoing trials. In the United States, surgical resection is often followed by adjuvant chemoradiation therapy or by a combination of neoadjuvant and adjuvant chemotherapy. Here we report on 4 patients with resected gastric adenocarcinoma who were treated with a combination of these 2 approaches, receiving neoadjuvant chemotherapy followed by adjuvant chemoradiation therapy...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28501087/the-role-of-radiotherapy-in-localized-esophageal-and-gastric-cancer
#5
REVIEW
John Ng, Percy Lee
Multimodality management has become a core treatment principle for locally advanced esophageal, gastroesophageal junction (GEJ), and gastric cancer. Radiotherapy serves an important role for optimizing patient outcomes. This article reviews the evolving role of radiotherapy in the multidisciplinary management of esophageal, GEJ, and gastric cancer, summarizing the results of recent clinical trials leading to contemporary accepted treatment approaches. A major theme is the evidence supporting the role of radiotherapy in combined modality management, particularly the trend toward its delivery in the neoadjuvant setting...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28486692/early-results-of-a-randomized-two-by-two-factorial-phase-ii-trial-comparing-neoadjuvant-chemotherapy-with-two-and-four-courses-of-cisplatin-s-1-and-docetaxel-cisplatin-s-1-as-neoadjuvant-chemotherapy-for-locally-advanced-gastric-cancer
#6
T Aoyama, K Nishikawa, K Fujitani, K Tanabe, S Ito, T Matsui, A Miki, H Nemoto, K Sakamaki, T Fukunaga, Y Kimura, N Hirabayashi, T Yoshikawa
Neoadjuvant chemotherapy (NAC) is a promising method of improving the survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) are both effective against metastatic gastric cancer. This report clarified the impact of these regimens on early endpoints, including the pathological responses, chemotherapy-related toxicities, and surgical results. Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m 2 at day 8)/S-1 (80 mg/m 2 for 21 days with 1 week rest) or docetaxel (40 mg/m 2 at day 1)/cisplatin (60 mg/m 2 at day 1)/S-1 (80 mg/m 2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy...
May 9, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28484222/in-silico-evaluation-of-dna-damage-inducible-transcript-4-gene-ddit4-as-prognostic-biomarker-in-several-malignancies
#7
Joseph A Pinto, Christian Rolfo, Luis E Raez, Alexandra Prado, Jhajaira M Araujo, Leny Bravo, Williams Fajardo, Zaida D Morante, Alfredo Aguilar, Silvia P Neciosup, Luis A Mas, Denisse Bretel, Justin M Balko, Henry L Gomez
DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described that DDIT4 expression is an independent prognostic factor for tripe negative breast cancer resistant to neoadjuvant chemotherapy. We herein report that high DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overall survival) in several cancer types. We performed in silico analysis in online platforms, in pooled datasets from KM Plotter and meta-analysis of individual datasets from SurvExpress...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28483410/neoadjuvant-chemotherapy-survival-benefit-in-gastric-cancer
#8
Manjulika Das
No abstract text is available yet for this article.
May 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28475005/impact-of-the-immune-cell-population-in-peripheral-blood-on-response-and-survival-in-patients-receiving-neoadjuvant-chemotherapy-for-advanced-gastric-cancer
#9
Qi He, Guoli Li, Xiang Ji, Long Ma, Xulin Wang, Yang Li, Chaogang Fan
We aimed to investigate the prognostic value of the immune cells population in peripheral blood from patients with advanced gastric cancer treated with neoadjuvant chemotherapy. A total of 105 patients with advanced gastric cancer were evaluated in this study. Blood samples were collected before and 1 week after the last dose of chemotherapy. The percentage of CD3+, CD3+CD4+, CD3+CD8+, and CD4+CD25+Foxp3+ T cells was assessed using flow cytometry analysis. The relationship between T cell subsets and clinical outcome was evaluated...
May 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28462649/postoperative-survival-following-perioperative-magic-versus-neoadjuvant-oe02-type-chemotherapy-in-oesophageal-adenocarcinoma
#10
A M Reece-Smith, J H Saunders, I N Soomro, C R Bowman, J P Duffy, P V Kaye, N T Welch, S Madhusudan, S L Parsons
The optimal management of resectable oesophageal adenocarcinoma is controversial, with many centres using neoadjuvant chemotherapy following the Medical Research Council (MRC) oesophageal working group (OE02) trial and the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. The more intensive MAGIC regimen is used primarily in gastric cancer but some also use it for oesophageal cancer. A database of cancer resections (2001-2013) provided information on survival of patients following either OE02 or MAGIC-type treatment...
May 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/28448662/effect-of-neoadjuvant-chemotherapy-followed-by-surgical-resection-on-survival-in-patients-with-limited-metastatic-gastric-or-gastroesophageal-junction-cancer-the-aio-flot3-trial
#11
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M Martens, Jan Stoehlmacher, Harald Schmalenberg, Kim B Luley, Nicole Prasnikar, Matthias Egger, Stephan Probst, Helmut Messmann, Markus Moehler, Wolfgang Fischbach, Jörg T Hartmann, Frank Mayer, Heinz-Gert Höffkes, Michael Koenigsmann, Dirk Arnold, Thomas W Kraus, Kersten Grimm, Stefan Berkhoff, Stefan Post, Elke Jäger, Wolf Bechstein, Ulrich Ronellenfitsch, Stefan Mönig, Ralf D Hofheinz
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. Design, Setting, and Participants: The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma...
April 27, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28447199/a-novel-reconstruction-technique-during-pancreaticoduodenectomy-after-roux-en-y-gastric-bypass-how-i-do-it
#12
George Younan, Susan Tsai, Douglas B Evans, Kathleen K Christians
The altered anatomy in patients after bariatric surgery who have undergone a Roux-en-Y gastric bypass may pose a technical challenge for surgical removal of the pancreatic head. We treat patients with pancreas cancer with multimodality therapy in a neoadjuvant fashion followed by pancreaticoduodenectomy (PD). In patients with Roux-en-Y gastric bypass anatomy, the gastric remnant is preserved and used for pancreaticogastrostomy reconstruction and subsequently drained by the same jejunal limb used for the hepaticojejunostomy...
April 26, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28447050/prognostic-impact-of-nodal-status-and-therapeutic-implications
#13
REVIEW
Katja Ott, Susanne Blank, Laura Ruspi, Margit Bauer, Leila Sisic, Thomas Schmidt
The prognostic impact of lymph node (LN) metastases in gastric cancer is generally accepted. In primarily resected patients the pN-category and LN ratio are independent prognostic factors. Number of involved LNs, number of resected LNs, lymphangiosis and micrometastases also influence the prognosis significantly. To guarantee a proper D2 lymphadenectomy (LAD) at least 25 LNs according to the German S3 guidelines for the treatment of gastric cancer should be removed. Also in neoadjuvantly treated patients the ypN-category and LN ratio play an important prognostic role, despite the fact that UICC staging system was development based only on primarily resected patients...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28355948/sequential-endoscopic-ultrasound-identifies-predictive-variables-for-relapse-free-follow-up-after-neoadjuvant-chemotherapy-in-gastric-cancer
#14
Wolfram Bohle, Ruben Zachmann, Wolfram G Zoller
BACKGROUND: The accuracy of endosonographic tumor staging after neoadjuvant therapy is less reliable than in primary staging. Therefore, the value of sequential endosonographic examinations after neaodjuvant chemotherapy in gastro-esophageal cancer is discussed controversially. Previous data suggest, that endoscopic ultrasound (EUS) after neoadjuvant treatment using other variables than classic uTN-criteria may identify patients with a better prognosis. METHODS: In 67 patients with locally advanced gastric cancer treated in curative intent, we performed EUS before and after neoadjuvant chemotherapy...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28353020/association-between-waiting-time-from-diagnosis-to-treatment-and-survival-in-patients-with-curable-gastric-cancer-a-population-based-study-in-the-netherlands
#15
H J F Brenkman, E Visser, P S N van Rossum, S Siesling, R van Hillegersberg, J P Ruurda
BACKGROUND: In the Netherlands, a maximum waiting time from diagnosis to treatment (WT) of 5 weeks is recommended for curative cancer treatment. This study aimed to evaluate the association between WT and overall survival (OS) in patients undergoing gastrectomy for cancer. METHODS: This nationwide study included data from patients diagnosed with curable gastric adenocarcinoma between 2005 and 2014 from the Netherlands Cancer Registry. Patients were divided into two groups: patients who received neoadjuvant therapy followed by gastrectomy, or patients who underwent gastrectomy as primary surgery...
March 28, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28337365/body-composition-as-a-prognostic-factor-of-neoadjuvant-chemotherapy-toxicity-and-outcome-in-patients-with-locally-advanced-gastric-cancer
#16
Carolina Palmela, Sónia Velho, Lisa Agostinho, Francisco Branco, Marta Santos, Maria Pia Costa Santos, Maria Helena Oliveira, João Strecht, Rui Maio, Marília Cravo, Vickie E Baracos
PURPOSE: Neoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes...
March 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28337360/perioperative-epirubicin-oxaliplatin-and-capecitabine-chemotherapy-in-locally-advanced-gastric-cancer-safety-and-feasibility-in-an-interim-survival-analysis
#17
Vikas Ostwal, Arvind Sahu, Anant Ramaswamy, Bhawna Sirohi, Subhadeep Bose, Vikas Talreja, Mahesh Goel, Shraddha Patkar, Ashwin Desouza, Shailesh V Shrikhande
PURPOSE: Perioperative chemotherapy improves survival outcomes in locally advanced (LA) gastric cancer. MATERIALS AND METHODS: We retrospectively analyzed patients with LA gastric cancer who were offered perioperative chemotherapy consisting of epirubicin, oxaliplatin, and capecitabine (EOX) from May 2013 to December 2015 at Tata Memorial Hospital in Mumbai. RESULTS: Among the 268 consecutive patients in our study, 260 patients (97.0%) completed neoadjuvant chemotherapy, 200 patients (74...
March 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28316218/-predictive-and-prognostic-significance-of-high-sensitivity-modified-glasgow-prognostic-score-hs-mgps-in-advanced-gastric-cancer-patients-treated-with-neoadjuvant-chemotherapy
#18
Y Cui, J Li, Y H Cao, M Y Liu, Z X Shi, T H Gao
Objective: To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer. Methods: 117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed...
March 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28292272/comparison-of-five-tumor-regression-grading-systems-for-gastric-adenocarcinoma-after-neoadjuvant-chemotherapy-a-retrospective-study-of-192-cases-from-national-cancer-center-in-china
#19
Yuelu Zhu, Yongkun Sun, Shangying Hu, Yong Jiang, Jiangying Yue, Xuemin Xue, Lin Yang, Liyan Xue
BACKGROUND: Neoadjuvant chemotherapy has been increasingly practiced on gastric cancer (GC), and histological evaluation to predict outcome is urgent in clinical practice. There are five classic tumor regression grading (TRG) systems, including Mandard-TRG system, the Japanese Gastric Cancer Association (JGCA)-TRG system, College of American Pathologists (CAP)-TRG system, China-TRG system and Becker-TRG system. METHODS: Totally, 192 patients of gastric adenocarcinoma (including adenocarcinoma of the esophagogastric junction) treated by neoadjuvant chemotherapy and surgery were evaluated using the above five TRG systems...
March 14, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28288188/evaluations-of-primary-lesions-by-endoscopy-clearly-distinguishes-prognosis-in-patients-with-gastric-cancer-who-receive-chemotherapy
#20
Tomomitsu Tahara, Tomoyuki Shibata, Masaaki Okubo, Tomohiko Kawamura, Noriyuki Horiguchi, Dai Yoshida, Takamitsu Ishizuka, Mitsuo Nagasaka, Yoshihito Nakagawa, Naoki Ohmiya
BACKGROUND: Chemotherapy may improve outcomes in gastric cancer (GC), especially for the patients with advanced stage. To explore useful predictive factor for GC performing chemotherapy, we compared the tumor responses assessed using computed tomography (CT) with endoscopy based criteria. METHODS: 192 GC patients performing chemotherapy were retrospectively studied. CT based response assessment was performed after 2 courses of treatment. Endoscopic evaluation according to The Japanese classification of gastric carcinoma was also performed at same period...
2017: PloS One
keyword
keyword
110856
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"